As a safe, non-addictive alternative to conventional insomnia treatments, Meloff® stands out as a compelling option. This new food supplement utilizes the benefits of Melissa officinalis (lemon balm) leveraging the Phytosome® technology to boost absorption and effectiveness. With its remarkable ability to enhance sleep quality, Meloff® is a natural choice for individuals seeking restful sleep and improved quality of life.
Bactorinol®, available as nasal drops since 2021 in Italy, has gained international interest and is now available in a convenient spray format.
Formulated with Winterized Lentisk Oil (WLO) from Pistacia lentiscus berries, it has been clinically proven to reduce biofilm formation and alleviate Chronic RhinoSinusitis (CRS) symptoms, with recent studies confirming significant improvements in both biofilm presence and overall symptom relief.
Berberol®, a nutraceutical combining Berberis aristata and Silybum marianum, has shown promise in improving glycemic control and reducing insulin resistance.
A recent meta-analysis highlights its effectiveness in lowering blood glucose and HbA1c levels, thanks to the synergistic action between berberine and silymarin. Berberol® is effective both as a standalone and adjunctive therapy, offering a valuable option for managing glycemic issues.
Bactorinol® is a medical device available as nasal drops, formulated with Winterized Lentisk Oil (WLO) derived from Pistacia Lentiscus berries. This unique ingredient has been shown to reduce biofilm formation and alleviate Chronic RhinoSinusitis (CRS) symptoms.
Recent research further supports its efficacy, demonstrating significant improvements in CRS outcomes, including a substantial reduction in biofilm presence and related symptoms.
Crispact®, a precision probiotic containing Lactobacillus crispatus M247, has been selected as a finalist for the CPHI Pharma Awards for the third time, following its recent success at the NutraIngredients Awards. This continued recognition highlights the strength of the research behind Crispact®, including a recent pivotal study on its role in assisted reproductive technology (ART), which has significantly enhanced the understanding of its applications in fertility treatments. Despite its wide-ranging evidence in other fields, this ART study marks a crucial development for the product.
There is growing interest in natural supplement for PCOS like Inositols and Berberine.
Inositols help improve insulin sensitivity, but may not be effective for all.
Berberine, particularly in its enhanced form as Berberine Phytosome®, offers broader benefits by improving insulin sensitivity, reducing androgen levels, and enhancing ovulation. This makes Sophy®, a unique clinically studied supplement featuring Berberine Phytosome®, a promising option for managing various aspects of PCOS.
Crispact®, containing Lactobacillus crispatus M247, is a precision probiotic that combats bacterial vaginosis (BV) by reducing the virulence of Gardnerella vaginalis. It achieves this by decreasing the expression of key virulence factors, vaginolysin and sialidase, and blocking pathogen adherence to vaginal epithelial cells.
Crispact® is highly effective in promoting vaginal health and preventing recurrent BV, earning the 2024 NutraIngredients Award for Best Finished Product of the Year for Microbiome Modulation.
Two of our products, Crispact® and Sophy®, won at NutraIngredients Awards Europe 2024, showcasing their excellence in women’s health solutions.
Crispact® is recognized for its ability to restore the vaginal microbiome and support HPV clearance, while Sophy® effectively addresses PCOS symptoms with its potent Berberine Phytosome®.
Discover PharmExtracta’s groundbreaking achievements! Two of our products, Crispact® and Sophy®, are finalists at NutraIngredients Awards Europe 2024.
Join us at Vitafoods, stand Q90, to witness how Crispact® and Sophy® revolutionize women’s well-being. Don’t miss the chance to explore our innovative solutions: mark your calendars and visit our booth to learn more.
Chasteberry extract, recognized by the EMA since 2010, is a potent ally against menstrual disorders and PMS, targeting prolactin and progesterone levels.
A recent study examined MonoSelect® Agnus in managing PMS, showcasing significant symptom reduction, especially with continuous usage, offering a promising treatment avenue.